Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
Key Highlights
- ➤Evotec awarded $2.9 million Gates Foundation grant for three-year drug safety project extension
- ➤Platform assesses potential fetal development risks using human stem cell-based testing
- ➤Initial collaboration screened more than 5,000 compounds across nine grantee programs
Expert Statements
Joanna Holbrook, Chief Scientific Officer of Evotec
“Identifying potential safety risks early in the drug development process is essential to the efficient advancement of better medicines for global health priorities. Our platform allows researchers to investigate potential effects on prenatal development based on the behavior of human cells, helping them make better-informed decisions about which drug candidates to pursue and minimizing the risk of costly and time-consuming changes in course later in the process. The continued funding support of the Gates Foundation is an important recognition of the potential value of this approach, and we are pleased to extend access to this technology for global health research.”
Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology PR Newswire
* New three-year grant from the Gates Foundation extends a 2023 project to help global health researchers predict potential fetal development risks posed by novel drug candidates * Evotec's human stem cell-based platform enables better-informed decisions regarding which drug candidates to advance into clinical testing * Continued collaboration underscores Evotec's capabilities in advanced human cell-based drug discovery technologies HAMBURG, Germany, Nov. 16, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has been awarded a new $2.9 million grant by the Gates Foundation to support continued use of its human stem cell-based New Approach Methodologies (NAMs) for identifying potential safety risks to fetal development in novel drug candidates. The funding extends a project initiated in 2023 for a further three years, providing researchers working on global health programs with continued access to technology that can help assess potential risks earlier in drug discovery.
Get started
Create a free account to read the full story.
